Sugi Predict

Sugi Predict / Compounds / SCHEMBL5864529

SCHEMBL5864529

SCHEMBL5864529

COc1cc2ncnc(Nc3ccccc3F)c2cc1OC

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 12/20 1.00
▸ FLT1 P17948 4/20 1.00
▸ EGFR P00533 7/20 0.97
▸ FGFR1 P11362 2/20 0.75
▸ RET P07949 6/20 0.73
▸ KIF5B P33176 4/20 0.73
▸ EPHB2 P29323 1/20 0.72
▸ FLT4 P35916 1/20 0.72
▸ HDAC3 O15379 4/20 0.70
▸ HDAC4 P56524 4/20 0.70
▸ HDAC1 Q13547 4/20 0.70
▸ HDAC7 Q8WUI4 4/20 0.70
▸ HDAC2 Q92769 4/20 0.70
▸ HDAC10 Q969S8 4/20 0.70
▸ HDAC11 Q96DB2 4/20 0.70
▸ HDAC8 Q9BY41 4/20 0.70
▸ HDAC6 Q9UBN7 4/20 0.70
▸ HDAC9 Q9UKV0 4/20 0.70
▸ HDAC5 Q9UQL6 4/20 0.70
▸ RAF1 P04049 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28451851 0.85 KDR (0.73) KDRFLT1EGFRFGFR1RET
SCHEMBL29428184 0.85 KDR (0.73) KDRFLT1EGFRFGFR1RET
SCHEMBL12200787 0.85 RET (0.74) KDRFLT1EGFRRETKIF5B
SCHEMBL7866068 0.85 KDR (0.80) KDRFLT1EGFRFGFR1RET
SCHEMBL5864525 0.85 KDR (1.00) KDRFLT1EGFRFGFR1RET
SCHEMBL7076160 0.84 RET (1.00) KDRFLT1EGFRRETKIF5B
SCHEMBL7116324 0.84 SRC (0.75) KDRFLT1EGFRRETKIF5B
SCHEMBL5865250 0.84 EGFR (1.00) KDRFLT1EGFRRETKIF5B
SCHEMBL7116313 0.84 RET (0.73) KDRFLT1EGFRRETKIF5B
SCHEMBL18158255 0.84 EGFR (0.73) KDRFLT1EGFRFGFR1RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040039002-A1 6,7-Dimethoxyquinazolines and therapeutic use thereof PARKER HUGHES INSTITUTE 2004-02-26 — — US claimed
JP-2002540103-A — — 2002-11-26 — — JP claimed
US-20020137757-A1 Quinazolines and therapeutic use thereof PARKER HUGHES INSTITUTE (US) 2002-09-26 — — US claimed
US-20020111360-A1 Quinazoline formulations and therapeutic use thereof PARKER HUGHES INSTITUTE 2002-08-15 — — US claimed
US-6358962-B2 ANTIALLERGENS; ANTITUMOR AGENTS; ANTICANCER AGENTS PARKER HUGHES INSTITUTE 2002-03-19 — — US claimed
EP-1163228-A1 QUINAZOLINES AND THERAPEUTIC USE THEREOF Parker Hughes Institute (US) 2001-12-19 — — EP claimed
EP-1162974-A1 QUINAZOLINE FORMULATIONS AND THERAPEUTIC USE THEREOF Parker Hughes Institute (US) 2001-12-19 — — EP claimed
US-20010016588-A1 Quinazolines and therapeutic use thereof HUGHES INSTITUTE (US) 2001-08-23 — — US claimed
US-6258820-B1 ANTITUMOR AGENTS PARKER HUGHES INSTITUTE 2001-07-10 — — US claimed
WO-2000056720-A1 QUINAZOLINES AND THERAPEUTIC USE THEREOF PARKER HUGHES INSTITUTE (US) 2000-09-28 — — WO claimed
WO-2000056338-A1 QUINAZOLINE FORMULATIONS AND THERAPEUTIC USE THEREOF PARKER HUGHES INSTITUTE (US) 2000-09-28 — — WO claimed
US-7038049-B2 Haloanilino quinazolines and therapeutic use thereof PARKER HUGHES INSTITUTE (US) 2006-05-02 — — US disclosed
US-20050075353-A1 Quinazolines and therapeutic use thereof PARKER HUGHES INSTITUTE (US) 2005-04-07 — — US disclosed
US-20040039002-A1 6,7-Dimethoxyquinazolines and therapeutic use thereof PARKER HUGHES INSTITUTE 2004-02-26 — — US disclosed
US-6638939-B2 Anticancer agents PARKER HUGHES INSTITUTE 2003-10-28 — — US disclosed
EP-1163228-A1 QUINAZOLINES AND THERAPEUTIC USE THEREOF Parker Hughes Institute (US) 2001-12-19 — — EP disclosed
US-20010016588-A1 Quinazolines and therapeutic use thereof HUGHES INSTITUTE (US) 2001-08-23 — — US disclosed
US-6258820-B1 ANTITUMOR AGENTS PARKER HUGHES INSTITUTE 2001-07-10 — — US disclosed
WO-2000056720-A1 QUINAZOLINES AND THERAPEUTIC USE THEREOF PARKER HUGHES INSTITUTE (US) 2000-09-28 — — WO disclosed
WO-2000056338-A1 QUINAZOLINE FORMULATIONS AND THERAPEUTIC USE THEREOF PARKER HUGHES INSTITUTE (US) 2000-09-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050075353-A1 Quinazolines and therapeutic use thereof HRH2, HRH4, HNMT KDR 3004/4885FLT1 3496/4885EGFR 1931/4885
US-20020111360-A1 Quinazoline formulations and therapeutic use thereof CMA1, MAST3, MAST1 KDR 2810/4885FLT1 2293/4885EGFR 3336/4885
US-20020137757-A1 Quinazolines and therapeutic use thereof HRH2, HRH4, HNMT KDR 3004/4885FLT1 3496/4885EGFR 1931/4885
US-20040039002-A1 6,7-Dimethoxyquinazolines and therapeutic use thereof HRH2, HNMT, HRH4 KDR 2273/4885FLT1 3973/4885EGFR 1601/4885
US-20010016588-A1 Quinazolines and therapeutic use thereof HRH2, HRH4, HNMT KDR 3004/4885FLT1 3496/4885EGFR 1931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.